Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status
-
- Emmanouilides Christos
- Department of Medical Oncology, Interbalkan Hospital, Thessaloniki, Greece
この論文をさがす
抄録
Radioimmunotherapy (RIT) treatment for lymphoma is a novel targeted therapeutic approach. Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when 90Y-ibritumomab tiuxetan (ZevalinTM, Y2B8) was approved in the USA and later in Europe, for the treatment of relapsed or refractory, low grade or transformed B-cell lymphoma. 90Y-ibritumomab tiuxetan utilizes a monoclonal anti-CD20 antibody to deliver β-emitting yttium-90 to the malignant B-cells. Clinical trials have demonstrated its efficacy, which is largely independent of the intrinsic activity of the anti-CD20 antibody. A similar anti-CD20 radiotherapeutic compound, 131I-tositumomab, was subsequently approved in the USA. The advantages of increased efficacy compared to the naked antibody are gained at the expense of myelotoxicity which is dose limiting but reversible. Studies exploring expanded applications of radioimmunotherapy have been recently completed or are under way. It is hoped that RIT will be an ideal agent for consolidation after chemotherapy for both indolent and aggressive non-Hodgkin lymphoma as well as a useful addition to preparatory high dose regimens prior to transplant. RIT has been shown to be an effective and clinically relevant complementary therapeutic approach for patients with lymphoma. [J Clin Exp Hematopathol 47(2) : 43-60, 2007]
収録刊行物
-
- Journal of Clinical and Experimental Hematopathology
-
Journal of Clinical and Experimental Hematopathology 47 (2), 43-60, 2007
日本リンパ網内系学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204700342528
-
- NII論文ID
- 10019969918
-
- NII書誌ID
- AA11556796
-
- ISSN
- 18809952
- 13464280
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可